http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016188231-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5521fc38db199c5a1b1d6c8a06c6c9b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 |
| filingDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b844a473c643dbb54c732d9aa8665cf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d1f724ffb5319d4179cafdfb133e860 |
| publicationDate | 2016-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016188231-A |
| titleOfInvention | Method for maintaining renal function using xanthine oxidoreductase inhibitor |
| abstract | The present invention provides an antihyperuricemia composition capable of maintaining renal function by administration of a therapeutically effective amount of a xanthine oxidoreductase inhibitor compound or a salt thereof. Treatment of 2- [3-cyano-4- (2-methylpropoxy) phenyl] -4-methylthiazole-5-carboxylic acid (generic name: febuxostat) or a pharmaceutically acceptable salt thereof Including an effective amount; the subject is suffering from-gout, acute gout arthritis, chronic gout joint disease or nodular gout;-renal function is serum creatinine level, creatinine clearance level and glomerular filtration rate (GFR) -The subject's GFR is maintained at a level of about 75% or higher when compared to the subject's baseline GFR level;-The subject's serum uric acid level is 2.6- A pharmaceutical composition administered to said subject for a period of time lower than or maintained at a level of 7.2 mg / dL and longer than 30 months. [Selection] Figure 2 |
| priorityDate | 2006-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 273.